NCT02324127

Brief Summary

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,100

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2012

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

December 14, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 24, 2014

Completed
Last Updated

December 24, 2014

Status Verified

December 1, 2014

Enrollment Period

2.2 years

First QC Date

December 14, 2014

Last Update Submit

December 23, 2014

Conditions

Liver Cancer

Outcome Measures

Primary Outcomes (1)

  • Hsp90α Concentration of plasma

    Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

    4 months

Study Arms (1)

liver cancer

EXPERIMENTAL

Detect plasma Hsp90α concentration of liver cancer patients

Device: hsp90

Interventions

hsp90DEVICE

Detect plasma Hsp90α concentration of lung cancer patients

Also known as: biomarker
liver cancer

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Liver cancer patients
  • Healthy volunteers,
  • Benign liver diseases patients

You may not qualify if:

  • Patients who Previously accepted radiotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhejiang Medical University Cancer Institute and Hospital

Hangzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver Diseases

Study Officials

  • Shusen Zhen, MD

    The first hospital of Zhejiang province

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 14, 2014

First Posted

December 24, 2014

Study Start

October 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

December 24, 2014

Record last verified: 2014-12

Locations

CN(1)